Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
GABA transporters (GATs) are membrane proteins responsible for the reuptake of GABA, the primary inhibitory neurotransmitter in the mammalian central nervous system. They play a crucial role in regulating extracellular GABA concentrations, thereby controlling synaptic transmission and maintaining neural circuit balance. There are four main plasma membrane GABA transporter subtypes: GAT1 (SLC6A1), GAT2 (SLC6A13), GAT3 (SLC6A11), and BGT1 (SLC6A12). These transporters clear released GABA from the synaptic cleft, terminating inhibitory signaling and maintaining homeostasis. Dysfunction or reversal of GAT function can contribute to neurological disorders like epilepsy. Inhibitors targeting these transporters, such as tiagabine, are used to modulate inhibition.
Inhibition of GABA reuptake, increasing extracellular GABA concentration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on GABA Transporters (GATs).